Evidence map›Paper›PMID 18467505›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2008

Gene therapy of Cav1.2 channel with VIP and VIP receptor agonists and antagonists: a novel approach to designing promotility and antimotility agents.

Xuan-Zheng Shi, Sushil K Sarna

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Developmental origins of colon smooth muscle dysfunction in IBS-like rats.American journal of physiology. Gastrointestinal and liver physiology · 2013
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Differential immune and genetic responses in rat models of Crohn's colitis and ulcerative colitis.American journal of physiology. Gastrointestinal and liver physiology · 2011
    Article
  17. Homeostatic and therapeutic roles of VIP in smooth muscle function: myo-neuroimmune interactions.American journal of physiology. Gastrointestinal and liver physiology · 2009
    Article
  18. Norepinephrine mediates the transcriptional effects of heterotypic chronic stress on colonic motor function.American journal of physiology. Gastrointestinal and liver physiology · 2009
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xuan-Zheng ShiEnteric Neuromuscular Disorders and Visceral Pain Center, Division of Gastroenterology, Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, TX 77555-1064, USA.
Sushil K Sarna
The University of Texas Medical Branch at Galveston · US

Funding

CONTROL OF COLONIC MOTILITY IN HEALTH AND DISEASER01DK032346 · NIDDK · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SARNA, SUSHIL K · 1986 to 2012
$4.0M
VIP-induced gene expression in colonic smooth muscle cellsR01DK072414 · NIDDK · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SARNA, SUSHIL K · 2005 to 2010
$1.9M
NIDDK NIH HHS DK-072414NIDDK NIH HHS DK-32346
6 · The paper itself

Abstract

Recent findings show that the enteric neurotransmitter VIP enhances gene transcription of the alpha1C subunit of Cav1.2 (L-type) Ca2+ channels in the primary cultures of human colonic circular smooth muscle cells and circular smooth muscle strips. In this study, we investigated whether systemic infusion of VIP in intact animals enhances the gene transcription and protein expression of these channels to accelerate colonic transit. We also investigated whether similar systemic infusions of VPAC1/2 receptor antagonist retards colonic transit by repressing the constitutive gene expression of the alpha1C subunit. We found that the systemic infusion of VIP for 7 days by a surgically implanted osmotic pump enhances the gene and protein expression of the alpha1C subunit and circular muscle contractility in the proximal and the middle rat colons, but not in the distal colon. A similar systemic infusion of VPAC1/2 receptor antagonist represses the expression of the alpha1C subunit and circular smooth muscle contractility in the proximal and the middle colons. The VIP infusion accelerates colonic transit and pellet defecation by rats, whereas the infusion of VPAC1/2 receptor antagonist retards colonic transit and pellet defecation. VPAC1 receptors, but not VPAC2 receptors, mediate the above gene transcription-induced promotility effects of VIP. We conclude that VIP and VPAC(1) receptor agonists may serve as potential promotility agents in constipation-like conditions, whereas VPAC receptor antagonists may serve as potential antimotility agents in diarrhea-like conditions produced by enhanced motility function.

Indexed as

AcetylcholineAnimalsCalcium Channels, L-TypeColonGastrointestinal MotilityGene Expression RegulationGenetic TherapyInfusion Pumps, ImplantableMaleMuscle ContractionMuscle, SmoothRatsRats, Sprague-DawleyReceptors, Vasoactive Intestinal Peptide, Type IIReceptors, Vasoactive Intestinal Polypeptide, Type IVasoactive Intestinal PeptideAcetylcholineCacna1c protein, ratCalcium Channels, L-TypeReceptors, Vasoactive Intestinal Peptide, Type IIReceptors, Vasoactive Intestinal Polypeptide, Type IVasoactive Intestinal PeptideWater

Identifiers

PMID18467505
PMCPMC2494720
OpenAlexW2050989570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.